The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies
Open accessPublished version of a preprint
Abstract
Background: Our understanding of the global scale of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection remains incomplete: Routine surveillance data underestimate infection and cannot infer on population immunity; there is a predominance of asymptomatic infections, and uneven access to diagnostics. We meta-analyzed SARS-CoV-2 seroprevalence studies, standardized to those described in the World Health Organization’s Unity protocol (WHO Unity) for general population seroepidemiological studies, to estimate the extent of population infection and seropositivity to the virus 2 years into the pandemic. Methods and findings: We conducted a systematic review and meta-analysis, searching MEDLINE, Embase, Web of Science, preprints, and grey literature for SARS-CoV-2 seroprevalence published between January 1, 2020 and May 20, 2022. The review protocol is registered with PROSPERO (CRD42020183634). We included general population cross-sectional and cohort studies meeting an assay quality threshold (90% sensitivity, 97% specificity; exceptions for humanitarian settings). We excluded studies with an unclear or closed population sample frame. Eligible studies—those aligned with the WHO Unity protocol—were extracted and critically appraised in duplicate, with risk of bias evaluated using a modified Joanna Briggs Institute checklist. We meta-analyzed seroprevalence by country and month, pooling to estimate regional and global seroprevalence over time; compared seroprevalence from infection to confirmed cases to estimate underascertainment; meta-analyzed differences in seroprevalence between demographic subgroups such as age and sex; and identified national factors associated with seroprevalence using meta-regression. We identified 513 full texts reporting 965 distinct seroprevalence studies (41% low- and middle-income countries [LMICs]) sampling 5,346,069 participants between January 2020 and April 2022, including 459 low/moderate risk of bias studies with national/subnational scope in further analysis. By September 2021, global SARS-CoV-2 seroprevalence from infection or vaccination was 59.2%, 95% CI [56.1% to 62.2%]. Overall seroprevalence rose steeply in 2021 due to infection in some regions (e.g., 26.6% [24.6 to 28.8] to 86.7% [84.6% to 88.5%] in Africa in December 2021) and vaccination and infection in others (e.g., 9.6% [8.3% to 11.0%] in June 2020 to 95.9% [92.6% to 97.8%] in December 2021, in European high-income countries [HICs]). After the emergence of Omicron in March 2022, infection-induced seroprevalence rose to 47.9% [41.0% to 54.9%] in Europe HIC and 33.7% [31.6% to 36.0%] in Americas HIC. In 2021 Quarter Three (July to September), median seroprevalence to cumulative incidence ratios ranged from around 2:1 in the Americas and Europe HICs to over 100:1 in Africa (LMICs). Children 0 to 9 years and adults 60+ were at lower risk of seropositivity than adults 20 to 29 ( p < 0.001 and p = 0.005, respectively). In a multivariable model using prevaccination data, stringent public health and social measures were associated with lower seroprevalence ( p = 0.02). The main limitations of our methodology include that some estimates were driven by certain countries or populations being overrepresented. Conclusions: In this study, we observed that global seroprevalence has risen considerably over time and with regional variation; however, over one-third of the global population are seronegative to the SARS-CoV-2 virus. Our estimates of infections based on seroprevalence far exceed reported Coronavirus Disease 2019 (COVID-19) cases. Quality and standardized seroprevalence studies are essential to inform COVID-19 response, particularly in resource-limited regions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Fitting Linear Mixed-Effects Models Using lme4
Bates, D., Mächler, M., Bolker, B., & Walker, S. (2015) · Journal of Statistical Software · doi:10.18637/jss.v067.i01 · Cited by 86,835
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Conducting Meta-Analyses in R with the metafor Package
Viechtbauer, W. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i03 · Cited by 20,464
Wood, S. N. (2011) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2010.00749.x · Cited by 7,537
How to perform a meta-analysis with R: a practical tutorial
Balduzzi, S., Rücker, G., & Schwarzer, G. (2019) · Evidence Based Mental Health · doi:10.1136/ebmental-2019-300117 · Cited by 5,827
Feature Selection with the Boruta Package
Kursa, M. B., & Rudnicki, W. R. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i11 · Cited by 5,659
WHO Coronavirus Disease (COVID-19) Dashboard
(2020) · Bangladesh Physiotherapy Journal · doi:10.46945/bpj.10.1.03.01 · Cited by 3,806
Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742
Munn, Z., Moola, S., Lisy, K., Riitano, D., & Tufanaru, C. (2015) · International Journal of Evidence-Based Healthcare · doi:10.1097/xeb.0000000000000054 · Cited by 3,131
Research works printed but not linked: 18
- N Bobrovitz, 2021, A systematic review and meta-analysis of SARS-CoV-2 seroprevalence studies aligned with the WHO population-based sero-epidemiological ‘Unity’ protocol CRD42020183634, PROSPERO
- SeroTracker Group, 2022, SeroTracker: Our Data (Our Protocol), Airtable
- COVID-19 Global Humanitarian Response Plan, 2020, United Nations Office for the Coordination of Humanitarian Affairs
- M Morgan, Sensitivity and specificity of multiple tests, In: Radiopaedia
- NRL, 2021, WHO COVID Evaluations Summary of Results, nrlquality
- HTG Aus AGD of, 2021, Post market review of COVID-19 point-of-care tests, Therapeutic Goods Administration (TGA). Australian Government Department of Health
- FIND, 2021, FIND evaluation of SARS-CoV-2 antibody (Ab) detection tests, FIND: Diagnosis for All
- N Bobrovitz, 2021, SeroTracker-ROB: reproducible decision rules for risk of bias assessment of seroprevalence studies, Epidemiology
- World Health Organization, 2021, Regional offices
- The World Bank, 2021, World Bank Country and Lending Groups
- World Health Organization, London School of Hygiene and Tropical Medicine, 2021, Public Health and Social Measures
- J Higgins, 2021, Cochrane Handbook for Systematic Reviews of Interventions (version 6.2), Cochrane
- WHO Headquarters (HQ), 2020, WHO COVID-19 Case definition
- H Ritchie, 2020, Coronavirus Pandemic (COVID-19), Our World in Data
- Institute for Health metrics and Evaluation (IHME), 2021, COVID-19: Estimating the historical time series of infections
- Institute for Health metrics and Evaluation (IHME), 2021, COVID-19 Estimates
- Puya-Dehgani-Mobaraki, 2022, Long-Term Persistence of IgG Antibodies in recovered COVID-19 individuals at 18 months and the impact of two-dose BNT162b2 (Pfizer-BioNTech) mRNA vaccination on the antibody response, Infectious Diseases (except HIV/AIDS)
- CJE Metcalf, 2017, Opportunities and challenges of a world serum bank–authors’ reply, Lancet, 389, 252, 10.1016/S0140-6736(17)30054-5 · doi:10.1016/s0140-6736(17)30054-5
Cited by
Bobrovitz, N., Ware, H., Ma, X., Li, Z., Hosseini, R., Cao, C., Selemon, A., Whelan, M., Premji, Z., Issa, H., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00801-5 · Cited by 614
Self-citationLevin, A. T., Owusu-Boaitey, N., Pugh, S., Fosdick, B. K., Zwi, A. B., Malani, A., Soman, S., Besançon, L., Kashnitsky, I., Ganesh, S., et al. (2022) · BMJ Global Health · doi:10.1136/bmjgh-2022-008477 · Cited by 208
Lewis, H., Ware, H., Whelan, M., Subissi, L., Li, Z., Ma, X., Nardone, A., Valenciano, M., Cheng, B., Noel, K., et al. (2022) · doi:10.1101/2022.02.14.22270934 · Cited by 177
Self-citationWang, W., Lusvarghi, S., Subramanian, R., Epsi, N. J., Wang, R., Goguet, E., Fries, A. C., Echegaray, F., Vassell, R., Coggins, S., et al. (2022) · doi:10.1101/2022.07.05.498883 · Cited by 68
Automation of Systematic Reviews with Large Language Models
Cao, C., Arora, R., Cento, P., Budak, A., Manta, K., Farahani, E., Cecere, M., Selemon, A., Sang, J., Gong, L. X., et al. (2025) · medRxiv · doi:10.1101/2025.06.13.25329541 · Cited by 33
Self-citation
Metadata
- Authors
- Bergeri, I., Whelan, M. G., Ware, H., Subissi, L., Nardone, A., Lewis, H. C., Li, Z., Ma, X., Valenciano, M., Cheng, B., Al Ariqi, L., Rashidian, A., Okeibunor, J., Azim, T., Wijesinghe, P., Le, L.-V., Vaughan, A., Pebody, R., Vicari, A., Yan, T., Yanes-Lane, M., Cao, C., Clifton, D. A., Cheng, M. P., Papenburg, J., Buckeridge, D., Bobrovitz, N., Arora, R. K., Van Kerkhove, M. D., & Unity Studies Collaborator Group
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2022-11-10
- Volume
- 19
- Issue
- 11
- Pages
- e1004107
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W4308706077
- Cited by
- 310
- References
- 45
- FWCI
- 13.72
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- WHO COVID-19 Solidarity Response Fund
- German Federal Ministry of Health COVID-19 Research and Development Fund
- World Health Organisation
- Canada’s COVID-19 Immunity Task Force through the Public Health Agency of Canada (2021-HQ-000056)
- Canadian Medical Association Joule Innovation Fund
- Robert Koch Institute
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies. https://app.cochat.ai/papers/10.1371/journal.pmed.1004107
- The paper
- Bergeri, I., Whelan, M. G., Ware, H., Subissi, L., Nardone, A., Lewis, H. C., Li, Z., Ma, X., Valenciano, M., Cheng, B., Al Ariqi, L., Rashidian, A., Okeibunor, J., Azim, T., Wijesinghe, P., Le, L.-V., Vaughan, A., Pebody, R., Vicari, A., . . . Unity Studies Collaborator Group. (2022). Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1004107
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.